Acadia Pharma (ACAD) Misses Q1 EPS by 7c, Revs Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
May 1, 2019 4:05 PM EDT
- 1Q19 Net Sales Grew to $63.0 Million, a 29% Increase Over 1Q18
-
Updated 2019 Net Sales Guidance to $280 Million to $300 Million
-
Completed Enrollment in Two Late-Stage Adjunctive Schizophrenia Studies
with Pimavanserin
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the first quarter ended March 31, 2019.
Weve commenced 2019 with significant momentum. The... More
